Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
“With 3 ongoing clinical trials, GAIA is one of the world’s most advanced cell therapy companies in the field of solid tumors. They have a very compelling allogeneic immune cell therapy strategy, which relies on GAIA-102 NK-like cells – a specific population of immune cells isolated from healthy donor blood samples that exhibit strong anti-tumor cytotoxic potency. Our Japanese team is very excited to start collaborating with GAIA scientists, and we strongly believe that GAIA’s innovative approach, combined with the C-Stem™ platform, could lead to fast and broad patient access to adoptive cell therapies against solid tumors”.
Share:
More News
“KEYTRUDA has helped transform the treatment of certain cancers, and we continue to pursue innovations that build on this breakthrough medicine to give patients and those who treat them better experiences,” said Dr. Marjorie Green, senior vice president and head of oncology, global clinical development, Merck Research Laboratories. “If approved,
“We are disappointed for ovarian cancer patients desperately lacking new treatment options. There has been a great deal of work across the industry in this immunologically cold tumor, yet there are still few treatment options that improve survival in this very difficult-to-treat tumor type. We are still on track to
“The improvement in survival seen in ROSELLA, without an increased safety burden, brings us closer to delivering a new standard-of-care treatment for patients with platinum-resistant ovarian cancer,” said Bill Guyer, PharmD, Corcept’s Chief Development Officer. “We deeply appreciate the patients and investigators who participated in the trial, and we look
“We are grateful for the ongoing guidance and support from the FDA and are very pleased that the agency is fully aligned on our plans related to the Phase 3 trial,” said Stacy Lindborg, Ph.D., president and chief executive officer of IMUNON. “The Phase 2 OVATION 2 study data are
